S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

$64.55
+0.12 (+0.19%)
(As of 04/19/2024 ET)
Today's Range
$64.40
$64.55
50-Day Range
$28.77
$64.55
52-Week Range
$6.71
$64.57
Volume
3.98 million shs
Average Volume
3.88 million shs
Market Capitalization
$4.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.33

Alpine Immune Sciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
22.0% Downside
$50.33 Price Target
Short Interest
Healthy
8.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Alpine Immune Sciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$5,192 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.74) to ($1.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.42 out of 5 stars

Medical Sector

674th out of 909 stocks

Pharmaceutical Preparations Industry

304th out of 425 stocks

ALPN stock logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

ALPN Stock Price History

ALPN Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Alpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading Volume
Alpine Immune Sciences (NASDAQ:ALPN) Shares Gap Up to $47.04
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.33
High Stock Price Target
$65.00
Low Stock Price Target
$18.00
Potential Upside/Downside
-22.0%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$-32,180,000.00
Pretax Margin
-54.49%

Debt

Sales & Book Value

Annual Sales
$58.88 million
Book Value
$5.64 per share

Miscellaneous

Free Float
37,820,000
Market Cap
$4.23 billion
Optionable
Optionable
Beta
1.14
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 56)
    Executive Chairman & CEO
    Comp: $778.2k
  • Dr. Stanford Peng M.D. (Age 53)
    Ph.D., President and Head of Research & Development
    Comp: $751.2k
  • Mr. Paul Rickey (Age 45)
    Senior VP, CFO, Treasurer & Secretary
    Comp: $577.1k
  • Ms. M. Christina Yi (Age 47)
    Chief Technology Officer
  • Temre Johnson
    Head of IR & Corporate Communications
  • Dr. Remy Durand Ph.D. (Age 39)
    Chief Business Officer
  • Dr. Wolfgang Dummer M.D. (Age 58)
    Ph.D., Chief Medical Officer

ALPN Stock Analysis - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price target for 2024?

11 Wall Street research analysts have issued 12 month price targets for Alpine Immune Sciences' stock. Their ALPN share price targets range from $18.00 to $65.00. On average, they anticipate the company's stock price to reach $50.33 in the next twelve months. This suggests that the stock has a possible downside of 22.0%.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2024?

Alpine Immune Sciences' stock was trading at $19.06 at the beginning of the year. Since then, ALPN shares have increased by 238.7% and is now trading at $64.55.
View the best growth stocks for 2024 here
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a drop in short interest in March. As of March 31st, there was short interest totaling 5,280,000 shares, a drop of 5.9% from the March 15th total of 5,610,000 shares. Based on an average daily volume of 1,200,000 shares, the days-to-cover ratio is currently 4.4 days.
View Alpine Immune Sciences' Short Interest
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) posted its earnings results on Monday, March, 18th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.32) by $0.47. The biotechnology company had revenue of $30.85 million for the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative trailing twelve-month return on equity of 15.54%.

What other stocks do shareholders of Alpine Immune Sciences own?
Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Banque Cantonale Vaudoise (0.03%), Mesirow Financial Investment Management Inc. (0.02%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Decheng Capital China Life Sci, James Paul Rickey, Life Sciences Viii L Frazier, Mitchell Gold, Orbimed Advisors Llc, Peter A Thompson and Robert E Conway.
View institutional ownership trends
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALPN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners